CASI Pharmaceuticals Inc. (CASIF) vs GT Biopharma, Inc. (GTBP)

CASI Pharmaceuticals Inc. and GT Biopharma, Inc. are both Biotechnology companies. CASI Pharmaceuticals Inc. and GT Biopharma, Inc. are of similar size ($12.4M and $12.3M). CASI Pharmaceuticals Inc. grew revenue faster over the last twelve months: −27.4% against −76.2%. GT Biopharma, Inc. has the higher net margin (0.00% vs −232.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, CASI Pharmaceuticals Inc. leads on 8 and GT Biopharma, Inc. on 8.

Valuation

Metric CASIF GTBP Biotechnology median
P/E n/m n/m 7.88
P/S 0.12 178.31 11.47
P/B n/m 3.00 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 1.81 96.13 10.73
Earnings yield (1,984.62%) (2,140.78%) (28.84%)
Free cash flow yield (3,717.40%) (133.29%) (23.03%)

Profitability

Metric CASIF GTBP Biotechnology median
Gross margin 48.65% 41.67% 65.16%
Operating margin (206.87%) 0.00% 0.00%
Net margin (232.03%) 0.00% 0.00%
Free cash flow margin (432.54%) 0.00% 0.00%
Return on equity 0.00% 102.03% (57.72%)
Return on assets 0.00% (176.27%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CASIF GTBP Biotechnology median
Revenue growth (TTM) (27.42%) (76.19%) 5.64%
EPS growth (last fiscal year) (1.17%) 3.75% —
Revenue growth, 5-year CAGR 6.47% 19.67% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CASIF GTBP Biotechnology median
Debt to equity (0.34) 0.00 0.00
Current ratio 0.15 2.61 4.73
Net debt to EBITDA (0.43) 0.56 0.96

Dividend

Metric CASIF GTBP Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CASIF GTBP Biotechnology median
Market cap 12.39m 12.32m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack